Skip to main content

DESARROLLO DE FARMACOS NEUROPROTECTORES CONTRA DIANAS ASTROCITARIAS MEDIANTE INTELIGENCIA ARTIFICIAL

PID2019-107633RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Vestibular CCK signaling drives motion sickness-like behavior in mice

  • Machuca Márquez, Pablo|||0000-0002-7980-3839
  • Sánchez Benito, Laura
  • Menardy, Fabien Louis Joseph|||0000-0002-8712-1344
  • Urpi, Andrea|||0000-0002-2437-7094
  • Girona, Mònica
  • Puighermanal Puigvert, Emma|||0000-0003-4271-9104
  • Appiah, Isabella|||0000-0002-4684-4992
  • Palmiter, Richard D.|||0000-0001-6587-0582
  • Sanz Iglesias, Elisenda|||0000-0002-7932-8556
  • Quintana Romero, Albert|||0000-0003-1674-7160
We live in an age where travel is paramount. However, one of the most disabling conditions inherent to traveling is motion sickness (MS). While studies have underscored the role of the vestibular system in the development of MS, the neuronal populations involved in motion-induced malaise remain largely unknown. Here, we describe the vestibular pathways eliciting MS responses and identify a key role for cholecystokinin (CCK)-expressing vestibular neurons. We reveal that a vestibulo-parabrachial (VN-PBN) CCKergic projection is sufficient to induce conditioned taste avoidance, likely through the activation of calcitonin gene-related peptide-expressing PBN neurons. Finally, we underscore the role of CCK-A receptor signaling as a druggable target to treat MS, providing insight on the neurobiological substrates of MS. Travel can induce motion sickness (MS) in susceptible individuals. MS is an evolutionary conserved mechanism caused by mismatches between motion-related sensory information and past visual and motion memory, triggering a malaise accompanied by hypolocomotion, hypothermia, hypophagia, and nausea. Vestibular nuclei (VN) are critical for the processing of movement input from the inner ear. Motion-induced activation of VN neurons recapitulates MS-related signs. However, the genetic identity of VN neurons mediating MS-related autonomic and aversive responses remains unknown. Here, we identify a central role of cholecystokinin (CCK)-expressing VN neurons in motion-induced malaise. Moreover, we show that CCK VN inputs onto the parabrachial nucleus activate Calca -expressing neurons and are sufficient to establish avoidance to novel food, which is prevented by CCK-A receptor antagonism. These observations provide greater insight into the neurobiological regulation of MS by identifying the neural substrates of MS and providing potential targets for treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dysfunctional LHX6 pallido-subthalamic projections mediate epileptic events in a mouse model of Leigh syndrome

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Reactive astrocyte nomenclature, definitions, and future directions

  • Escartin, C
  • Galea, Elena
  • Lakatos, A.
  • O’Callaghan, J.P.
  • Petzold, G.C.
  • Serrano-Pozo, Alberto
  • Steinhäuser, C.
  • Volterra, A.
  • Carmignoto, G.
  • Agarwal, A.
  • Allen, N.J
  • Araque, Alfonso
  • Barbeito, Luis
  • Barzilai, Ari
  • Bergles, D. E.
  • Bonvento, Gilles
  • Butt, A.M.
  • Chen, W.T.
  • Cohen-Salmon, M.
  • Cunningham, C.
  • Deneen, B.
  • De Strooper, B.
  • Díaz-Castro, Blanca
  • Farina, C.
  • Freeman, Mark
  • Gallo, V.
  • Goldman, J.E.
  • Goldman, S.A.
  • Götz, Magdalena
  • Gutiérrez, A.
  • Haydon, P. G.
  • Heiland, D.H.
  • Hol, E.M.
  • Holt, M.G.
  • Lino, M.
  • Kastanenka, K.V.
  • Kettenmann, H.
  • Khakh, B.S.
  • Koizumi, S.
  • Lee, C.J.
  • Liddelow, S.A.
  • MacVicar, B.A.
  • Magistretti, P.
  • Messing, A.
  • Mishra, A.
  • Molofsky, A.V.
  • Murai, K.K.
  • Norris, C.M.
  • Okada, S.
Reactive astrocytes are astrocytes undergoing morphological, molecular, and functional remodeling in response to injury, disease, or infection of the CNS. Although this remodeling was first described over a century ago, uncertainties and controversies remain regarding the contribution of reactive astrocytes to CNS diseases, repair, and aging. It is also unclear whether fixed categories of reactive astrocytes exist and, if so, how to identify them. We point out the shortcomings of binary divisions of reactive astrocytes into good-vs-bad, neurotoxic-vs-neuroprotective or A1-vs-A2. We advocate, instead, that research on reactive astrocytes include assessment of multiple molecular and functional parameters—preferably in vivo—plus multivariate statistics and determination of impact on pathological hallmarks in relevant models. These guidelines may spur the discovery of astrocyte-based biomarkers as well as astrocyte-targeting therapies that abrogate detrimental actions of reactive astrocytes, potentiate their neuro- and glioprotective actions, and restore or augment their homeostatic, modulatory, and defensive functions., Funding: CNRS, CEA, ANR, and France Alzheimer to CE.; MCINN (PID2019-107633RB-I00) and Generalitat de Catalunya (2017-SGR547, Grup de demències Sant Pau) to E.G. US Centers for Disease Control and Prevention to J. P.O. Alzheimer’s Association (AACF-17-524184) and NIH-NIA (K08AG064039) to A.S.-P. DFG (SPP1757, STE 552/5, STE 552/4), EU (H2020-MSCA-ITN project 722053 EU-GliaPhD) and BMBF (16GW0182 CONNEXIN) to C.S. Swiss National Science Foundation grant 31003A 173124/1; SNSF NCCR ‘Transcure’ (51NF40-160620); Synapsis Foundation Heidi Seiler-Stiftung 2018-PI01 to A.Volterra. NIH-NINDS (NS084030), Dr. Miriam and Sheldon G. Adelson Medical Foundation and Wings for Life to M.V.S. The authors thank T. Yohannan of Alpha Language Services, Barcelona, for expert copy editing.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models

  • Puighermanal, Emma
  • Luna Sánchez, Marta
  • Gella, Alejandro
  • van der Walt, Gunter
  • Urpi, Andrea
  • Royo, María
  • Tena-Morraja, Paula
  • Appiah, Isabella
  • de Donato, María Helena
  • Menardy, Fabien
  • Bianchi, Patrizia
  • Esteve-Codina, Anna
  • Rodríguez-Pascau, Laura
  • Vergara, Cristina
  • Gómez-Pallarès, Mercè
  • Marsicano, Giovanni
  • Bellocchio, Luigi
  • Martinell, Marc
  • Sanz, Elisenda
  • Jurado, Sandra
  • Soriano, Francesc Xavier
  • Pizcueta, Pilar
  • Quintana, Albert
Mutations in mitochondrial energy-producing genes lead to a heterogeneous group of untreatable disorders known as primary mitochondrial diseases (MD). Leigh syndrome (LS) is the most common pediatric MD and is characterized by progressive neuromuscular affectation and premature death. Here, we show that daily cannabidiol (CBD) administration significantly extends lifespan and ameliorates pathology in two LS mouse models, and improves cellular function in fibroblasts from LS patients. CBD delays motor decline and neurodegenerative signs, improves social deficits and breathing abnormalities, decreases thermally induced seizures, and improves neuropathology in affected brain regions. Mechanistically, we identify peroxisome proliferator-activated receptor gamma (PPARγ) as a key nuclear receptor mediating CBD's beneficial effects, while also providing proof of dysregulated PPARγ expression and activity as a common feature in both mouse neurons and fibroblasts from LS patients. Taken together, our results provide the first evidence for CBD as a potential treatment for LS., This work was supported by three MINECO Ramon y Cajal fellowships (RYC2020-029596-I; E.P., RYC2019-028501-I; E.S., and RyC-2012-11873; A.Q.), a Beatriu de Pinós fellowship from University and Research Grants Catalan Management Agency (#2017BP00132; E.P.) Marie Sklodowska-Curie Individual Fellowship (H2020-MSCA-IF-2014-658352; E.S., H2020-MSCA-IF-2020-101030783, M.L-S., H2020-MSCA-COFUND-2014-665919, A.G.), pre-doctoral fellowships (2018FI_B 00452 to AU, 2024 FI-1 00645 to GvdW). E.P received funds from MICINN (PID2021-125079OA-I00). E.S received funds from MICIU Proyectos I + D + i “Retos Investigacion” (RTI2018-101838-J-I00) and Ministerio de Ciencia e Innovación (MICINN) (PID2019-107633RB-I00 and PID2022-142544OB-I00). A.Q. is a recipient of an ICREA Academia award and received funds from the European Research Council (Starting grant NEUROMITO, ERC-2014-StG-638106), Grants SAF2014-57981P; SAF2017-88108-R, PID2020-114977RB-I00, RTC2019-006825-1, PDC2021-121883-I0, RED2022-134786-T, funded by MICIU/AEI /10.13039/5011000110330 and by MICIU/AEI /10.13039/501100011033 and Next GenerationEU/ PRTR, AGAUR (2017SGR-323, 2021SGR-720), Fundació TV3-La Marató (202030), and “la Caixa” Foundation (ID 100010434), under the agreement LCF/PR/HR20/52400018., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Dysfunctional LHX6 pallido-subthalamic projections mediate epileptic events in a mouse model of Leigh syndrome

  • Sánchez-Benito, Laura
  • González-Torres, Melania
  • Fernández-González, Irene
  • Cutando, Laura
  • Royo, María
  • Compte, Joan
  • Vila, Miquel
  • Jurado, Sandra
  • Sanz, Elisenda
  • Quintana, Albert
Deficits in the mitochondrial energy-generating machinery cause mitochondrial disease, a group of untreatable and usually fatal disorders. Refractory epileptic events are a common neurological presentation of mitochondrial disease, including Leigh syndrome, a severe form of mitochondrial disease associated with epilepsy. However, the neuronal substrates and circuits for mitochondrial disease-induced epilepsy remain unclear. Here, using mouse models of Leigh syndrome that lack mitochondrial complex I subunit NDUFS4 in a constitutive or conditional manner, we demonstrated that mitochondrial dysfunction leads to a reduction of GABAergic neurons in the rostral external globus pallidus (GPe) and identified a specific affectation of pallidal Lhx6-expressing inhibitory neurons contributing to altered GPe excitability. Our findings revealed that viral vector-mediated Ndufs4 reexpression in the GPe effectively prevented seizures and improved survival in the models. Additionally, we highlight the subthalamic nucleus (STN) as a critical structure in the neural circuit involved in mitochondrial epilepsy, as its inhibition effectively reduces epileptic events. Thus, we have identified a role for pallido-subthalamic projections in epilepsy development in the context of mitochondrial dysfunction. Our results suggest STN inhibition as a potential therapeutic intervention for refractory epilepsy in patients with mitochondrial disease, providing promising leads in the quest to identify effective treatments., This work is the result of NIH funding, in whole or in part, and is subject to the NIH Public Access Policy. Through acceptance of this federal funding, the NIH has been given a right to make the work publicly available in PubMed Central. Two Ministerio de Economía y Competitividad Ramon y Cajal fellowships (RyC2019-028501-I to ES and RyC-2012-11873 to AQ). A Ministerio de Ciencia e Innovación (MICINN) Ramon y Cajal fellowship (RYC2022-037332-I to LC). Two predoctoral fellowships from Ministerio de Ciencia, Innovación y Universidades (MICIU) (PRE2018-083179 to LSB and PRE2020-094293 to IFG). An MICIU predoctoral fellowship (FPU19/03990 to MGT). ES was supported by MICIU Proyectos I+D+i “Retos Investigacion” (RTI2018-101838-J-I00, to ES) and Ministerio de Ciencia e Innovación (PID2019-107633RB-I00 and PID2022-142544OB-I00). AQ received funds from the European Research Council (starting grant 1178 NEUROMITO, ERC-2014-StG-638106), SAF2017-88108-R, PID2020-114977RB-I00, PID2023-151947OB-I00, RED2022-134786-T, RED2024-154130-T, 381180 funded by MICIU/AEI/10.13039/5011000110330 and by MICIU/AEI /10.13039/501100011033 1181 and Next GenerationEU/PRTR,2 AGAUR (2017SGR-323, 2021SGR-720), Fundació TV3-La 1182 Marató (202030), and “la Caixa” Foundation (ID 100010434), under the agreement 1183 LCF/PR/HR20/52400018. AQ is a recipient of an Institució Catalana de Recerca i Estudis Avançats Academia award., Peer reviewed